Medy-Tox, Inc.

Technology Overview

1. Background of Technology

Neuronox ® (Medutoxin® for Korean market) is Clostridium botulinum type A neurotoxin complex which was developed by Medy-Tox's proprietary technology and approved by KFDA in 2006. This product has already been approved by 13 countries involving India, Columbia, Thailand and also is expected to be approved by Brasilian healthcare authority, ANVISA in 3rd quarter of 2009. Neuronox ® has shown clinically proven efficacy and safety to be comparable to Allergan's BOTOX. Botulinum toxin products are used for more than 50 therapeutic indications involving strasbismus, cerebral palsy, cervical dystonia, blepharospasm, hemifacial spasm, tremors, tics, migrane, tension headache, achalasia, chronic anal fissure, hyperhidrosis, parkinsonism, multiple sclerosis, and cosmetic surgery.

In addition to current product development, Medy-Tox has developed next generation botulinum toxin product with better safety and efficacy since 2007. Medy-Tox is seeking partnership for co-development and marketing of current product (Neuronox ®) in US, EU, Canada, Japan, China, and next-generation botulinum toxin products in worldwide markets. Medt-Tox is also seeking partner(s) possessing innovative formulation and delivery technology for development collaboration of advanced product of botulinum toxin.

2. Description on Technology Applied

Botulinum toxin based thrapeutics related R/D

3. Differential Point, Superiority or Characteristics of Technology Applied

New production process absent from TSE risk

New advanced formulations absent from TSE risk